Close Menu

NEW YORK – The last few quarters haven't been easy for Enzo Biochem — the company's year-over-year revenues fell 7 percent in its fiscal fourth quarter (ended July 31), sank 14 percent in Q3, and barely ticked up 1 percent in Q2. The COVID-19 pandemic seemed to hit the diagnostics company hard, adversely affecting its clinical services revenues, diagnostic testing volumes, and product revenues.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.